{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:24:20Z","timestamp":1792643060607,"version":"4.5.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T00:00:00Z","timestamp":1605398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81730003"],"award-info":[{"award-number":["81730003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2017ZX09304021"],"award-info":[{"award-number":["2017ZX09304021"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Antifungal prophylaxis may result in breakthrough infections in hematology patients with severe agranulocytosis, with few studies assessing risk factors and clinical outcomes of breakthrough candidemia. We described the distribution of Candida species, assessed risk factors for mortality in such patients, and determined differences in the incidence and mortality of breakthrough candidemia between patients who did or did not receive an allogeneic hematopoietic stem cell transplant.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We collected clinical and microbiological data of patients with hematologic malignancies and breakthrough candidemia from a single center. Seven-day and 30-day follow-up outcomes were recorded; the incidence and mortality of breakthrough candidemia between patients who did or did not undergo an allogeneic transplant were compared. Kaplan-Meier survival estimates were used to generate survival curves, and predictors were identified using Cox regression analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 71 enrolled patients, 17 received allogeneic transplants. Incidences of breakthrough candidemia were 17 of 2924 (0.58%) and 54 of 12\u2009015 (0.45%) in the transplant and nontransplant groups, respectively (P = .35). The most common isolate was Candida tropicalis, and antifungal agent combinations were the most common first-line treatment. Cumulative mortality rates of patients were 21.1% and 31.0% at days 7 and 30, respectively, and they significantly differed between both groups. Septic shock, central venous catheter removal, and granulocyte recovery were significantly associated with 7-day mortality; the latter 2 remained independent predictors of 30-day mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Breakthrough candidemia-related mortality was higher in the allogeneic transplant group, although the incidence was not significantly different between the groups. Prompt and adequate antifungal treatment with catheter removal may reduce mortality.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciaa1523","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T20:13:10Z","timestamp":1603915990000},"page":"S394-S399","source":"Crossref","is-referenced-by-count":32,"title":["Clinical Characteristics and Outcomes of Breakthrough Candidemia in 71 Hematologic Malignancy Patients and\/or Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Single-center Retrospective Study From China, 2011\u20132018"],"prefix":"10.1093","volume":"71","author":[{"given":"Xiao-Chen","family":"Chen","sequence":"first","affiliation":[{"name":"National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China"},{"name":"Key Laboratory of Stem Cells and Biomedical Materials of Jiangsu Province and Chinese Ministry of Science and Technology, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Pei","family":"Wu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China"},{"name":"Key Laboratory of Stem Cells and Biomedical Materials of Jiangsu Province and Chinese Ministry of Science and Technology, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,23]]},"reference":[{"issue":"Suppl 6","key":"2020122314492965300_CIT0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12642","article-title":"Up to date epidemiology, diagnosis and management of invasive fungal infections","volume":"20","author":"Oren","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2020122314492965300_CIT0002","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"2020122314492965300_CIT0003","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020122314492965300_CIT0004","doi-asserted-by":"crossref","first-page":"O50","DOI":"10.1111\/1469-0691.12312","article-title":"A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies","volume":"20","author":"Gamaletsou","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2020122314492965300_CIT0005","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1002\/cncr.24507","article-title":"Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001\u20132007): stable incidence but changing epidemiology of a still frequently lethal infection.","volume":"115","author":"Sipsas","year":"2009","journal-title":"Cancer"},{"key":"2020122314492965300_CIT0006","doi-asserted-by":"crossref","first-page":"491.e1","DOI":"10.1016\/j.cmi.2014.12.027","article-title":"Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain","volume":"21","author":"Puig-Asensio","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2020122314492965300_CIT0007","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.hemonc.2015.06.006","article-title":"Epidemiological and mycological characteristics of candidemia in patients with hematological malignancies attending a tertiary-care center in India","volume":"8","author":"Dewan","year":"2015","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2020122314492965300_CIT0008","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/myc.12318","article-title":"Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens","volume":"58","author":"Corzo-Le\u00f3n","year":"2015","journal-title":"Mycoses"},{"key":"2020122314492965300_CIT0009","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/mmy\/myx038","article-title":"Risk factors and clinical outcomes of breakthrough yeast bloodstream infections in patients with hematological malignancies in the era of newer antifungal agents","volume":"56","author":"Kim","year":"2018","journal-title":"Med Mycol"},{"key":"2020122314492965300_CIT0010","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1086\/320757","article-title":"Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia","volume":"32","author":"Uzun","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020122314492965300_CIT0011","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s00134-017-4743-y","article-title":"The risk and clinical outcome of candidemia depending on underlying malignancy","volume":"43","author":"Lortholary","year":"2017","journal-title":"Intensive Care Med"},{"key":"2020122314492965300_CIT0012","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10096-004-1103-y","article-title":"Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study","volume":"23","author":"Tortorano","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020122314492965300_CIT0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020122314492965300_CIT0014","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1469-0691.2012.03906.x","article-title":"Risk factors for and clinical implications of\u2002mixed\u2002Candida\/bacterial bloodstream infections","volume":"19","author":"Kim","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2020122314492965300_CIT0015","first-page":"378","article-title":"Clinical significance of breakthrough fungemia caused by azole-resistant Candida tropicalis in patients with hematologic malignancies","volume":"89","author":"Myoken","year":"2004","journal-title":"Haematologica"},{"key":"2020122314492965300_CIT0016","first-page":"287","article-title":"Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies","volume":"91","author":"Myoken","year":"2006","journal-title":"Haematologica"},{"key":"2020122314492965300_CIT0017","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ijantimicag.2014.05.015","article-title":"Breakthrough candidaemia caused by phenotypically susceptible Candida spp. in patients with haematological malignancies does not correlate with established interpretive breakpoints","volume":"44","author":"Gamaletsou","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2020122314492965300_CIT0018","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jinf.2011.11.002","article-title":"Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer","volume":"64","author":"Chitasombat","year":"2012","journal-title":"J Infect"},{"key":"2020122314492965300_CIT0019","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1586\/eri.11.124","article-title":"Uncommon yeast infections in hematological patients: from diagnosis to treatment","volume":"9","author":"Caira","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2020122314492965300_CIT0020","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"2020122314492965300_CIT0021","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/1469-0691.12360","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections","volume":"20","author":"Arendrup","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2020122314492965300_CIT0022","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020122314492965300_CIT0023","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/1469-0691.12041","article-title":"ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after hematopoietic stem cell transplantation (HCT)","volume":"18","author":"Ullmann","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2020122314492965300_CIT0024","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/653935","article-title":"Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials","volume":"51","author":"Nucci","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020122314492965300_CIT0025","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020122314492965300_CIT0026","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/jac\/dkq053","article-title":"Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death","volume":"65","author":"Slavin","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2020122314492965300_CIT0027","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1128\/AAC.05947-11","article-title":"Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection","volume":"56","author":"Ben-Ami","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020122314492965300_CIT0028","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13054-016-1324-3","article-title":"Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions","volume":"20","author":"Le\u00f3n","year":"2016","journal-title":"Crit Care"},{"key":"2020122314492965300_CIT0029","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/jof4010027","article-title":"Non-culture diagnostics for invasive candidiasis: promise and unintended consequences","volume":"4","author":"Clancy","year":"2018","journal-title":"J Fungi"},{"key":"2020122314492965300_CIT0030","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkw188","article-title":"Discontinuation of empirical antifungal therapy in ICU patients using 1,3-\u03b2-d-glucan","volume":"71","author":"Nucci","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020122314492965300_CIT0031","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jinf.2018.01.011","article-title":"Usefulness of \u03b2-D-glucan for diagnosis and follow-up of invasive candidiasis in onco-haematological patients","volume":"76","author":"Guitard","year":"2018","journal-title":"J Infect"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/Supplement_4\/S394\/35098905\/ciaa1523.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/Supplement_4\/S394\/35098905\/ciaa1523.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T19:52:33Z","timestamp":1608753153000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/Supplement_4\/S394\/6046205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,15]]},"references-count":31,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2020,12,23]]},"published-print":{"date-parts":[[2020,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1523","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11,15]]},"published":{"date-parts":[[2020,11,15]]}}}